# Breast Neoplasms trials: 1,729 new since Nov 2024

Updated November 9, 2026.

1,729 clinical studies in Breast Neoplasms were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 254 have an industry sponsor and 1,312 are recruiting or about to. The newest, NCT07924527, was posted on November 9, 2026: Predicting Benefit From Anthracycline-Free Adjuvant Chemotherapy in High-Risk HER2-Negative Breast Cancer (Peking Union Medical College Hospital).

## The full list

New Breast Neoplasms clinical trials: 1,729 rows for $86.45, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 75 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/breast-neoplasms

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 1,729
- Industry sponsored: 254
- Recruiting or not yet: 1,312
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 1,729, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07924527 | Predicting Benefit From Anthracycline-Free Adjuvant Chemotherapy in High-Risk HER2-Negative Breast Cancer | Peking Union Medical College Hospital | Observational | Active not recruiting | Breast Neoplasms, HER2-negative Breast Cancer | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924527) |
| November 6, 2026 | NCT07923643 | Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain | Assiut University | Not applicable | Not yet recruiting | Breast Cancer, Postoperative Pain, Chronic Postoperative Pain, Quality of Recovery | 60 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923643) |
| November 6, 2026 | NCT07923214 | A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors | Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer, Other Solid Tumors | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923214) |
| November 5, 2026 | NCT07920094 | Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of... | Sir Run Run Shaw Hospital | Not applicable | Recruiting | Breast Cancer | 422 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920094) |
| November 5, 2026 | NCT07919730 | Rowing-Based Exercise Intervention on Health and Quality of Life in Breast Cancer Survivors | Università Cattolica di Milano | Not applicable | Completed | Breast Cancer, Breast Cancer Survivors | 20 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919730) |
| November 5, 2026 | NCT07918989 | A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation Therapy After... | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Breast Cancer, Breast Cancer Female | 138 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918989) |
| November 5, 2026 | NCT07918079 | Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy | Fudan University | Phase 2 | Not yet recruiting | Breast Cancer | 84 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918079) |
| November 5, 2026 | NCT07917845 | Evaluation of Massage Therapy for Cancer Related Fatigue in Breast Cancer Survivors | Wake Forest University Health Sciences | Not applicable | Not yet recruiting | Breast Cancer, Fatigue in Cancer Survivors | 34 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917845) |
| November 4, 2026 | NCT07917117 | Improved Facial Skin Quality and Quality of Life After VYC-12L Treatment in Breast Cancer Survivors | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Observational | Recruiting | Quality of Life, Breast Neoplasms, Skin Aging, Hyaluronic Acid | 50 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917117) |
| November 4, 2026 | NCT07917026 | Continuous Controlled Cooling for Prevention of Chemotherapy-Induced Peripheral Neuropathy | Vastra Gotaland Region | Not applicable | Not yet recruiting | Chemotherapy Induced Peripheral Neuropathy (CIPN) | 148 | Sweden | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917026) |
| November 4, 2026 | NCT07916714 | Breast Cancer Real-World Insights and Decision Guidance Evaluation in Hong Kong | AstraZeneca | Observational | Not yet recruiting | Breast Neoplasms | 48,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916714) |
| November 4, 2026 | NCT07916337 | 3D Versus 2D Strain Echocardiography for Early Detection of Cardiotoxicity During Cancer Therapy | Region Skane | Observational | Recruiting | Cancer Related Cardiovascular Toxicity, Anthracycline Related Cardiotoxicity in Breast Cancer, Breast Cancer... | 130 | Sweden | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916337) |
| November 4, 2026 | NCT07915739 | Internal Mammary Node Irradiation After Neoadjuvant Systemic Therapy for Breast Cancer | Mahidol University | Phase 3 | Not yet recruiting | Breast Neoplasms | 1,760 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915739) |
| November 4, 2026 | NCT07915297 | Safety and Biodistribution of \[68Ga\]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC) | Luminance Biosciences Inc | Phase 1 | Not yet recruiting | Metastatic Breast Cancer | 10 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915297) |
| November 3, 2026 | NCT07914309 | Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer | Washington University School of Medicine | Phase 2 | Not yet recruiting | Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC), Breast Cancer | 17 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914309) |
| November 3, 2026 | NCT07911631 | Effects of a Mindful Self-Compassion Intervention on Psychological Adjustment in Breast Cancer Survivors | Chung Yuan Christian University | Not applicable | Recruiting | Breast Cancer | 80 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911631) |
| November 2, 2026 | NCT07910565 | Prospective Study to Evaluate the Clinical Utility of ctDNA Tumor Fraction (TF) for Detection of Estrogen Receptor 1 (ESR1) Mutations in... | Yale University | Not applicable | Not yet recruiting | Breast Cancer, Metastatic Breast Cancer, HR+/HER- Metastatic Breast Cancer | 155 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910565) |
| November 2, 2026 | NCT07909889 | Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer | Aarhus University Hospital | Phase 2 | Not yet recruiting | Breast Cancer (Early Breast Cancer), Obesity | 32 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909889) |
| November 2, 2026 | NCT07909785 | AKU Study - Acupuncture for Aromatase Inhibitor-Induced Musculoskeletal Syndrome | Masaryk Memorial Cancer Institute | Not applicable | Active not recruiting | Aromatase Inhibitor-Associated Musculoskeletal Syndrome, Arthralgia Syndrome, Early Breast Cancer (EBC) | 200 | Czechia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909785) |
| November 2, 2026 | NCT07909408 | Psilocybin FCR Early-Stage Breast Cancer | NYU Langone Health | Phase 2 | Not yet recruiting | Early-stage Breast Cancer, Fear of Cancer Recurrence, Anxiety, Depression | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909408) |
| October 30, 2026 | NCT07907419 | Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening | Ataturk University | Not applicable | Not yet recruiting | Breast Cancer Screening, Breast Cancer Awareness, Health Belief Model | 64 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907419) |
| October 30, 2026 | NCT07907354 | Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer | Yunnan Cancer Hospital | Phase 2 | Not yet recruiting | Breast Neoplasms, Advanced Breast Cancer, HER2-positive Breast Cancer, HER2-low Breast Cancer | 56 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907354) |
| October 30, 2026 | NCT07906990 | Culinary And Lifestyle Medicine Education for Cancer Risk Reduction in Survivors of Breast Cancer | Case Comprehensive Cancer Center | Not applicable | Not yet recruiting | Breast Cancer | 44 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906990) |
| October 29, 2026 | NCT07905313 | Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and... | Azienda Ospedaliero-Universitaria Careggi | Phase 2 | Not yet recruiting | Breast Cancer (Advanced/Metastatic) | 60 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905313) |
| October 29, 2026 | NCT07905001 | A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer | Prelude Therapeutics Incorporated | Phase 1 | Recruiting | Breast Cancer, Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, HR-positive Breast Cancer... | 242 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905001) |
| October 29, 2026 | NCT07902661 | Impact of Intraoperative Neurotization on Sensory Recovery of the Nipple and Breast Skin in Patients Undergoing Nipple Sparing Mastectomy... | Gangnam Severance Hospital | Not applicable | Not yet recruiting | Breast Cancer | 110 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902661) |
| October 28, 2026 | NCT07900516 | A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant... | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Breast Cancer | 48 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900516) |
| October 28, 2026 | NCT07899892 | A Study of 68Ga-FAPI Breast PET/MRI Scans in People With Breast Cancer | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Breast Cancer, Invasive Breast Cancer | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899892) |
| October 27, 2026 | NCT07899463 | ESR1 Mutations in Metastatic Hormone Receptor-Positive Breast Cancer in the Greek Population | Hellenic Cooperative Oncology Group | Observational | Recruiting | ESR1 Gene Mutation, Breast Cancer (Locally Advanced or Metastatic), Hormon Receptor Positive Breast Cancer | 500 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899463) |
| October 27, 2026 | NCT07899151 | Decision Support for Chemoprevention | Columbia University | Not applicable | Recruiting | Breast Cancer | 240 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899151) |
| October 27, 2026 | NCT07899099 | Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer | Zheng Yabing | Observational | Recruiting | Breast Cancer, Chemotherapy-induced Neutropenia | 200 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899099) |
| October 27, 2026 | NCT07899047 | Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Observational | Not yet recruiting | Breast Cancer, HER2-negative Breast Cancer, Advanced Breast Cancer | 1,372 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899047) |
| October 27, 2026 | NCT07898943 | Evaluation of the Effect of Antibiotic Prophylaxis During Lumpectomy for Breast Cancer: Prospective Randomised Double-blind Noninferiority... | University Hospital, Clermont-Ferrand | Phase 3 | Not yet recruiting | Breast Cancer, Breast Surgery, Surgical Site Infection (SSI), Surgical Site Infection Prevention | 1,600 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898943) |
| October 27, 2026 | NCT07898410 | Clinical Trial of an Upper Limb Measurement Device | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not applicable | Completed | Upper Limb Volume Measurement | 220 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898410) |
| October 27, 2026 | NCT07897890 | Testing Health-Related Interventions: Voices of Equity Needed to Overcome Weight-bias in Obesity-Cancer Care | Indiana University | Not applicable | Completed | Obesity & Overweight, Breast Cancer | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897890) |
| October 27, 2026 | NCT07897721 | A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors | Pfizer | Phase 1 | Not yet recruiting | Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic... | 268 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897721) |
| October 27, 2026 | NCT07897344 | Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy | Josephine Connolly-Schoonen | Not applicable | Recruiting | Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897344) |
| October 27, 2026 | NCT07896772 | Anti-Müllerian Hormone in Breast Cancer Clinical Practice | Masaryk Memorial Cancer Institute | Observational | Recruiting | Breast Cancer | 200 | Czechia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896772) |
| October 27, 2026 | NCT07896668 | Pucotenlimab and Anlotinib in Combination With Chemotherapy | Zhejiang Cancer Hospital | Phase 2 | Recruiting | Breast Cancer | 34 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896668) |
| October 26, 2026 | NCT07895511 | A Study of Skipping Radiation Therapy in People With Breast Cancer | Memorial Sloan Kettering Cancer Center | Not applicable | Recruiting | HER2-positive Breast Cancer, Breast Cancer | 136 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895511) |
| October 26, 2026 | NCT07895160 | Organ Culture for Endocrine Resistant Next Line: A Treatment Selection Study in Metastatic Breast Cancer | Tel-Aviv Sourasky Medical Center | Not applicable | Recruiting | Metastatic Breast Cancer, Hormon Receptor Positive Breast Cancer | 39 | Israel | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895160) |
| October 26, 2026 | NCT07894328 | A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Breast Cancer | 1,050 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894328) |
| October 26, 2026 | NCT07894133 | Gait Parameters in Breast Cancer Receiving Chemotherapy Patients | Adly A Adam | Observational | Recruiting | Breast Cancer, Chemotherapy, Biodex Gait Trainer, Gait Parameters | 360 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894133) |
| October 26, 2026 | NCT07893730 | Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches | University College Cork | Phase 2 | Not yet recruiting | Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC) | 50 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893730) |
| October 23, 2026 | NCT07893327 | Evaluation of the Effect of Regular Physical Exercise in Breast Cancer. | Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares | Not applicable | Recruiting | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | 150 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893327) |
| October 23, 2026 | NCT07892274 | Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | Not yet recruiting | Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer | 226 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892274) |
| October 23, 2026 | NCT07892157 | Cancer Patient Navigation and Readiness | Universitas Muhammadiyah Semarang | Not applicable | Completed | Breast Cancer, Breast Cancer and Rehabilitation, Transition Care, Breast Cancer - Female, Newly Diagnosed Breast Cancer | 64 | Indonesia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892157) |
| October 22, 2026 | NCT07890597 | A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative... | Pfizer | Phase 3 | Not yet recruiting | Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) | 3,800 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890597) |
| October 22, 2026 | NCT07889115 | Evaluation of the Effect of Amantadine in the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients | Al-Azhar University | Phase 2 | Not yet recruiting | Breast Cancer, Peripheral Neuropathy Due to Chemotherapy, VAS Score | 80 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889115) |
| October 22, 2026 | NCT07888881 | An Overview of Vaccination Coverage Among Patients Receiving Treatment for Breast Cancer at the ICO: Identifying Factors Associated With... | Institut Cancerologie de l'Ouest | Observational | Not yet recruiting | Breast Cancer | 312 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888881) |
| October 21, 2026 | NCT07884968 | Multimodal Respiratory Physiotherapy in Women Receiving Radiotherapy for Breast Cancer (RESPIRA-BC) | University of Alcala | Not applicable | Completed | Breast Neoplasms | 22 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884968) |
| October 20, 2026 | NCT07884487 | Surgical Margin Assessment Using Intra-operative High-resolution PET/CT in Patients With Cancers Referred to Surgical Resection, an... | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Not applicable | Active not recruiting | Breast Cancer, Head and Neck Cancers, Lung Cancer, Sarcoma, Liver Metastases From Colorectal Cancer, Gastro Intestinal... | 250 | Belgium | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884487) |
| October 20, 2026 | NCT07884201 | Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment | Fudan University | Phase 2 | Not yet recruiting | Breast Cancer, TNBC - Triple-Negative Breast Cancer, Immunotherapy | 572 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884201) |
| October 20, 2026 | NCT07883512 | EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction) | Virginia Commonwealth University | Phase 2 | Not yet recruiting | Breast Cancer, Supportive Care in Cancer | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883512) |
| October 20, 2026 | NCT07883460 | Improving Combined PET/CT and MRI of the Breast Using Dedicated Breast Positioning and Image Registration | Universität Münster | Not applicable | Not yet recruiting | Breast Cancer, Breast - Female | 20 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883460) |
| October 20, 2026 | NCT07883109 | Podcast-Based Psychosocial Support for Women Newly Diagnosed With Breast Cancer | Mei Man | Not applicable | Not yet recruiting | Breast Cancer | 80 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883109) |
| October 20, 2026 | NCT07882420 | Role of Artificial Intelligence in Breast Cancer Screening Via Mammography | Centre Antoine Lacassagne | Not applicable | Not yet recruiting | Breast Cancer | 1,222 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882420) |
| October 20, 2026 | NCT07882147 | Diagnostic Accuracy and Utility of ZTE Added to Routine MRI | Amal Ahmed Helmy | Observational | Not yet recruiting | Breast Cancer, MRI Imaging | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882147) |
| October 20, 2026 | NCT07882069 | Effect of ACTIVE-Care on Cancer-Related Fatigue, Hope, and Psychological Resilience in Adolescents With Acute Lymphoblastic Leukemia | Selcuk University | Not applicable | Completed | Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Adolescent, Resilience... | 70 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882069) |
| October 19, 2026 | NCT07881679 | Breast MRI for Early Detection of Breast Cancer in Thuringia | Jena University Hospital | Observational | Active not recruiting | Breast Cancer | 750 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881679) |
| October 19, 2026 | NCT07881341 | Anatomy Impact on RT Breast Cancer | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Observational | Recruiting | Breast Cancer | 30 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881341) |
| October 19, 2026 | NCT07881237 | Effect of Serratus and Pectoralis II Plane Block Versus Pectoralis II Alone on Acute Postoperative Pain After Mastectomy | Lebanese American University | Not applicable | Not yet recruiting | Mastectomy, Mastectomy Plus Axillary Lymph Node Dissection, Nerve Block; Pain Medication, Pectoralis Nerve Block... | 80 | Lebanon | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881237) |
| October 19, 2026 | NCT07880821 | Perioperative Mirogabalin for Pain Relief After Modified Radical Mastectomy | Cairo University | Not applicable | Not yet recruiting | Breast Cancer, Post Operative Pain | 50 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880821) |
| October 19, 2026 | NCT07880106 | Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Observational | Not yet recruiting | Lung Cancer Non-small Cell, Colorectal Cancer, Stomach Cancer, Hepatocellular Carcinoma, Breast Cancer | 2,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880106) |
| October 19, 2026 | NCT07879963 | Safety and Effectiveness Study of Single-Port Surgical System in Breast Tumor Surgery | haiyanli | Not applicable | Not yet recruiting | Breast Neoplasms | 25 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879963) |
| October 19, 2026 | NCT07879937 | Artificial Intelligence Integration in Breast Cancer Screening: The ANIHTA Study | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Not yet recruiting | Breast Neoplasms | 200,075 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879937) |
| October 16, 2026 | NCT07878377 | Screening and the Future of Enhanced MRI for Early Breast Cancer Detection | Radboud University Medical Center | Not applicable | Not yet recruiting | Breast Cancer Detection, Breast Cancer, Screening Strategy | 2,628 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07878377) |
| October 16, 2026 | NCT07877376 | Impact of Cognitive Impairment on Chronic Pain in Breast Cancer | Nadine ATTAL | Observational | Recruiting | Breast Cancer | 182 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877376) |
| October 15, 2026 | NCT07876986 | Feasibility and Effectiveness of Sentinel Lymph Node Biopsy in Inflammatory Breast Cancer | Case Comprehensive Cancer Center | Not applicable | Not yet recruiting | Breast Cancer | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876986) |
| October 15, 2026 | NCT07876596 | A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080 | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Breast Cancer | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876596) |
| October 15, 2026 | NCT07876375 | UPPER EXTREMITY FUNCTION AND LYMPHEDEMA IN BREAST CANCER SURVIVORS | Pamukkale University | Observational | Completed | Breast Cancer, Breast Cancer Female | 175 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876375) |
| October 15, 2026 | NCT07876349 | EHR Intervention to Increase HBOC Genetic Testing | Columbia University | Not applicable | Recruiting | Breast Cancer, Ovarian Cancer, Hereditary Cancer Syndrome | 55 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876349) |
| October 15, 2026 | NCT07875244 | MAMMI-BB PET for Monitoring Response to Neoadjuvant Therapy in Breast Cancer | Fudan University | Not applicable | Active not recruiting | Breast Cancer, Neoadjuvant Therapy, Axilla; Breast | 1,024 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875244) |
| October 14, 2026 | NCT07874256 | Non-Contrast-Enhanced Breast MRI in the Evaluation of Newly Diagnosed Breast Cancer: A Pilot Study | Massachusetts General Hospital | Not applicable | Not yet recruiting | Breast Cancer, Breast Cancer Detection | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874256) |
| October 13, 2026 | NCT07870148 | Cross Immune Response Between Breast Carcinoma and Thyroid Autoimmunity: Impact on Prognosis and Treatment | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Not applicable | Recruiting | Breast Cancer | 496 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870148) |
| October 9, 2026 | NCT07869186 | Dermatological Effects and Quality of Life in Oncology Patients | European Institute of Oncology | Not applicable | Not yet recruiting | Breast Cancer, Ovarian Cancer, NSCLC (Non-small Cell Lung Cancer), Melanoma (Skin Cancer), Gynecological Cancer | 300 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869186) |
| October 9, 2026 | NCT07868159 | Plant-derived Nutrients in the Prevention and Prognosis of Breast Cancer in Women. | Keda Yu | Not applicable | Active not recruiting | Breast Cancer | 639 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868159) |
| October 9, 2026 | NCT07867925 | Predicting Endocrine Resistance Using Molecular Imaging and Liquid Biopsy in Metastatic Breast Cancer | Asan Medical Center | Observational | Not yet recruiting | Metastatic Breast Cancer (HR+/ HER2-) | 100 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867925) |
| October 9, 2026 | NCT07867262 | A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally... | Genentech, Inc. | Phase 1 | Not yet recruiting | Advanced or Metastatic Breast Cancer | 165 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867262) |
| October 8, 2026 | NCT07865988 | Efficacy of High-Dose Melatonin in Alleviating Radiotherapy-Induced Fatigue in Breast Cancer Patients | Menoufia University | Phase 2/3 | Completed | Breast Cancer, Radiotherapy Induced Fatigue | 51 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865988) |
| October 8, 2026 | NCT07865884 | Tissue Validation of Mammographic Breast Arterial Calcification in Mastectomy Specimens | Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital | Observational | Not yet recruiting | Breast Cancer, Vascular Calcification, Coronary Artery Calcification, Atherosclerosis Cardiovascular Disease | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865884) |
| October 8, 2026 | NCT07864909 | Physical Activity Education and Quality of Life Study in Breast Cancer Chemotherapy Patients | International Hellenic University | Not applicable | Active not recruiting | Breast Cancer | 115 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864909) |
| October 7, 2026 | NCT07862426 | Incentive Spirometry With and Without Transcutaneous Electric Diaphragmatic Stimulation in Post-mastectomy Patients | University of Lahore | Not applicable | Active not recruiting | Breast Cancer, Post-Mastectomy | 58 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862426) |
| October 6, 2026 | NCT07861932 | A Phase 1/2a Study of K-1728 in Advanced Solid Tumors | KymaThera, Inc. | Phase 1/2 | Not yet recruiting | Breast Neoplasms, Solid Tumors, PIK3CA Gene Mutation | 110 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861932) |
| October 6, 2026 | NCT07861139 | Comparative Study of QL1209 and Perjeta® in Healthy Male Participants | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Breast Cancer | 80 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861139) |
| October 6, 2026 | NCT07860866 | Blood Biomarkers for Breast Cancer Treatment Response | University of Pittsburgh | Observational | Not yet recruiting | Breast Cancer (Advanced/Metastatic), ER Positive | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07860866) |
| October 5, 2026 | NCT07859319 | Evaluation of the Efficacy and Acceptability of a Phytotherapy Combining Devil's Claw, Blackcurrant and Meadowsweet for the Management of... | Hospices Civils de Lyon | Phase 4 | Not yet recruiting | Hormone Therapy-induced Arthralgia, Phytotherapy, Symptom Management, Adjuvant Treatment, Patient Acceptability, Joint... | 105 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859319) |
| October 5, 2026 | NCT07859098 | Examining a New Insomnia Treatment for People Living With Secondary Breast Cancer. | University of Strathclyde | Not applicable | Not yet recruiting | Insomnia, Breast Cancer Metastatic Breast Cancer | 50 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859098) |
| October 5, 2026 | NCT07859046 | 18F-FES PET/CT in the Treatment Planning, and Response Assessment of ER-Positive Breast Cancer | Hunan Cancer Hospital | Observational | Enrolling by invitation | Breast Cancer | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859046) |
| October 5, 2026 | NCT07858825 | Design and Pilot Implementation of a Chatbot to Support Breast Cancer Screening Among Black Women | University of Washington | Not applicable | Not yet recruiting | Breast Cancer | 873 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858825) |
| October 5, 2026 | NCT07857226 | Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer | Hebei Medical University Fourth Hospital | Phase 2 | Not yet recruiting | Breast Cancer | 31 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857226) |
| October 2, 2026 | NCT07856303 | SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response | Fudan University | Phase 2 | Not yet recruiting | HER2-positive Breast Cancer, Early Breast Cancer (EBC) | 358 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856303) |
| October 2, 2026 | NCT07856225 | Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer | Fundación Santa Fe de Bogota | Observational | Recruiting | Breast Neoplasms, Triple Negative Breast Neoplasms, HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer | 370 | Colombia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856225) |
| October 2, 2026 | NCT07856160 | De-escalation of Axillary Dissection for Node-positive Breast Cancer | University of Nebraska | Not applicable | Not yet recruiting | Breast Cancer by AJCC V8 Anatomic Stage, Breast Cancer | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856160) |
| September 30, 2026 | NCT07850869 | A Real-World Observational Study of Intratumoral H101 Oncolytic Adenovirus Combined With Immune Checkpoint Inhibitors for Advanced... | Jie Yuan，MD | Observational | Recruiting | Breast Cancer (Locally Advanced or Metastatic) | 15 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850869) |
| September 30, 2026 | NCT07850323 | Safety and Effectiveness of Robotic-Assisted Remote Surgery for Breast Tumors | Guangzhou Women and Children's Medical Center | Observational | Completed | Breast Neoplasms | 25 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850323) |
| September 30, 2026 | NCT07850154 | Impact of Robotic Versus Endoscopic Surgery on Nipple Nerve Function Following Nipple-Sparing Mastectomy for Breast Cancer | Guangzhou Women and Children's Medical Center | Not applicable | Not yet recruiting | Breast Neoplasms | 374 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850154) |
| September 30, 2026 | NCT07848984 | Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in... | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Not yet recruiting | Breast Neoplasms | 190 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848984) |
| September 29, 2026 | NCT07848243 | Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes | Peking University Cancer Hospital & Institute | Phase 2 | Recruiting | Lung Cancer (NSCLC), Cervical Squamous Cell Cancer, Melanoma (Skin Cancer), Breast Cancer, Gastrointestinal Cancers | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848243) |
| September 29, 2026 | NCT07848061 | A Master Regulator of Lipid-Associated Macrophage Function in Cancer | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Not yet recruiting | Breast Cancer, Head & Neck Cancer | 120 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848061) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Fudan University | 61 | November 5, 2026 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 25 | October 27, 2026 |
| Novartis Pharmaceuticals | 24 | September 3, 2026 |
| Memorial Sloan Kettering Cancer Center | 19 | November 5, 2026 |
| The First Affiliated Hospital with Nanjing Medical University | 18 | October 28, 2026 |
| UNC Lineberger Comprehensive Cancer Center | 18 | July 6, 2026 |
| Assiut University | 15 | November 6, 2026 |
| Tianjin Medical University Cancer Institute and Hospital | 15 | September 21, 2026 |
| European Institute of Oncology | 14 | October 9, 2026 |
| Sun Yat-sen University | 14 | July 29, 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 14 | June 29, 2026 |
| AstraZeneca | 13 | November 4, 2026 |
| Peking University Cancer Hospital & Institute | 13 | September 29, 2026 |
| Pfizer | 12 | October 27, 2026 |
| M.D. Anderson Cancer Center | 12 | June 5, 2026 |
| Xijing Hospital | 12 | April 15, 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 11 | September 30, 2026 |
| Peking University People's Hospital | 11 | September 28, 2026 |
| Institute of Oncology Ljubljana | 11 | July 29, 2026 |
| Henan Cancer Hospital | 11 | July 16, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 721 | November 6, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 449 | November 9, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 245 | November 5, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 108 | November 4, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 88 | November 6, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 67 | October 6, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 28 | October 5, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 13 | August 24, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 10 | October 8, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 389 | November 5, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 388 | November 9, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 114 | November 5, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 104 | October 30, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 96 | October 27, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 94 | November 4, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 54 | November 6, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 53 | October 9, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 49 | October 20, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 49 | September 18, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 44 | November 3, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 42 | November 4, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 39 | October 5, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 30 | September 3, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 28 | September 16, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 27 | October 20, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 24 | October 27, 2026 |
| [Sweden](https://specstream.ai/data/clinical-trials/country/sweden) | 23 | November 4, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 20 | July 14, 2026 |
| [Ireland](https://specstream.ai/data/clinical-trials/country/ireland) | 19 | September 25, 2026 |
| [Singapore](https://specstream.ai/data/clinical-trials/country/singapore) | 18 | September 22, 2026 |
| [Pakistan](https://specstream.ai/data/clinical-trials/country/pakistan) | 17 | October 7, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 16 | November 2, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 16 | June 15, 2026 |
| [Russia](https://specstream.ai/data/clinical-trials/country/russia) | 15 | September 15, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).